Literature DB >> 25171841

Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity.

Min-Chul Kim1, Yu-Na Lee2, Hye Suk Hwang2, Young-Tae Lee2, Eun-Ju Ko2, Yu-Jin Jung2, Min Kyoung Cho2, Yu-Jin Kim2, Jong Seok Lee2, Suk-Hoon Ha3, Sang-Moo Kang4.   

Abstract

Immunity in humans with annual vaccination does not provide effective protection against antigenically distinct strains. As an approach to improve cross-protection in the presence of pre-existing strain-specific immunity, we investigated the efficacy of heterologous and heterosubtypic protection in previously vaccinated mice at earlier times after subsequent immunization with conserved-antigenic target influenza M2 ectodomain (M2e) virus-like particle vaccine (M2e5× VLP). Immunization of mice with H1N1 split vaccine induced virus specific antibodies to homologous influenza virus but did not provide heterosubtypic hemagglutination inhibiting antibody responses and cross-protection. However, subsequent M2e5× VLP immunization induced an M2e specific antibody response as well as interferon-γ (IFN-γ) producing cells in systemic and mucosal sites. Upon lethal challenge with H3N2 or H5N1 subtype influenza viruses, subsequently immunized mice with M2e5× VLP were well protected against heterosubtypic influenza viruses. These results provide evidence that non-seasonal immunization with M2e5× VLP, an experimental candidate for universal vaccine, is a promising approach for broadening the cross-protection even in the presence of strain-specific immunity.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cross protection; Influenza vaccine; M2e5× VLPs; Pre-existing immunity

Mesh:

Substances:

Year:  2014        PMID: 25171841      PMCID: PMC4177275          DOI: 10.1016/j.vaccine.2014.08.030

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  30 in total

1.  Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection.

Authors:  T M Moran; H Park; A Fernandez-Sesma; J L Schulman
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

2.  Mouse adaptation of the Asian influenza virus.

Authors:  H S WEN; S P WANG
Journal:  J Infect Dis       Date:  1959 Jul-Aug       Impact factor: 5.226

Review 3.  Adjuvants--a classification and review of their modes of action.

Authors:  J C Cox; A R Coulter
Journal:  Vaccine       Date:  1997-02       Impact factor: 3.641

4.  Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions.

Authors:  K G Nicholson; D A Tyrrell; P Harrison; C W Potter; R Jennings; A Clark; G C Schild; J M Wood; R Yetts; V Seagroatt; A Huggins; S G Anderson
Journal:  J Biol Stand       Date:  1979-04

5.  Human infection with influenza H9N2.

Authors:  M Peiris; K Y Yuen; C W Leung; K H Chan; P L Ip; R W Lai; W K Orr; K F Shortridge
Journal:  Lancet       Date:  1999-09-11       Impact factor: 79.321

6.  Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial.

Authors:  Iain Stephenson; Karl G Nicholson; Reinhardt Glück; Robert Mischler; Robert W Newman; Abraham M Palache; Neville Q Verlander; Fiona Warburton; John M Wood; Maria C Zambon
Journal:  Lancet       Date:  2003-12-13       Impact factor: 79.321

7.  Codon bias and frequency-dependent selection on the hemagglutinin epitopes of influenza A virus.

Authors:  Joshua B Plotkin; Jonathan Dushoff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-14       Impact factor: 11.205

8.  Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome.

Authors:  Ron A M Fouchier; Peter M Schneeberger; Frans W Rozendaal; Jan M Broekman; Stiena A G Kemink; Vincent Munster; Thijs Kuiken; Guus F Rimmelzwaan; Martin Schutten; Gerard J J Van Doornum; Guus Koch; Arnold Bosman; Marion Koopmans; Albert D M E Osterhaus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-26       Impact factor: 11.205

9.  Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells.

Authors:  T L Stevens; A Bossie; V M Sanders; R Fernandez-Botran; R L Coffman; T R Mosmann; E S Vitetta
Journal:  Nature       Date:  1988-07-21       Impact factor: 49.962

Review 10.  Avian influenza virus infections in humans.

Authors:  Samson S Y Wong; Kwok-Yung Yuen
Journal:  Chest       Date:  2006-01       Impact factor: 9.410

View more
  20 in total

Review 1.  Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design.

Authors:  Sinthujan Jegaskanda; Hillary A Vanderven; Adam K Wheatley; Stephen J Kent
Journal:  Hum Vaccin Immunother       Date:  2017-03-23       Impact factor: 3.452

2.  Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.

Authors:  Wenqian Tao; Brett L Hurst; Akhilesh Kumar Shakya; Md Jasim Uddin; Rohan S J Ingrole; Mayra Hernandez-Sanabria; Ravi P Arya; Lynn Bimler; Silke Paust; E Bart Tarbet; Harvinder Singh Gill
Journal:  Antiviral Res       Date:  2017-02-02       Impact factor: 5.970

3.  Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.

Authors:  Min-Chul Kim; Yu-Na Lee; Yu-Jin Kim; Hyo-Jick Choi; Ki-Hye Kim; Youn-Jeong Lee; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2017-10-26       Impact factor: 5.970

Review 4.  Universal influenza vaccines: from viruses to nanoparticles.

Authors:  Ye Wang; Lei Deng; Sang-Moo Kang; Bao-Zhong Wang
Journal:  Expert Rev Vaccines       Date:  2018-11-02       Impact factor: 5.217

5.  Supplementation of inactivated influenza vaccine with norovirus P particle-M2e chimeric vaccine enhances protection against heterologous virus challenge in chickens.

Authors:  Mohamed Elaish; John M Ngunjiri; Ahmed Ali; Ming Xia; Mahmoud Ibrahim; Hyesun Jang; Jagadish Hiremath; Santosh Dhakal; Yosra A Helmy; Xi Jiang; Gourapura J Renukaradhya; Chang-Won Lee
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

6.  Cross-Protective Efficacy of Influenza Virus M2e Containing Virus-Like Particles Is Superior to Hemagglutinin Vaccines and Variable Depending on the Genetic Backgrounds of Mice.

Authors:  Yu-Jin Kim; Young-Tae Lee; Min-Chul Kim; Yu-Na Lee; Ki-Hye Kim; Eun-Ju Ko; Jae-Min Song; Sang-Moo Kang
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

Review 7.  Systems biology from virus to humans.

Authors:  Youri Lee; Yu-Jin Kim; Yu-Jin Jung; Ki-Hye Kim; Young-Man Kwon; Seung Il Kim; Sang-Moo Kang
Journal:  J Anal Sci Technol       Date:  2015-02-05

8.  Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1.

Authors:  Yong-Dae Gwon; Sehyun Kim; Yeondong Cho; Yoonki Heo; Hansam Cho; Kihoon Park; Hee-Jung Lee; Jiwon Choi; Haryoung Poo; Young Bong Kim
Journal:  PLoS One       Date:  2016-05-05       Impact factor: 3.240

Review 9.  Mechanisms of Cross-protection by Influenza Virus M2-based Vaccines.

Authors:  Yu-Na Lee; Min-Chul Kim; Young-Tae Lee; Yu-Jin Kim; Sang-Moo Kang
Journal:  Immune Netw       Date:  2015-10-26       Impact factor: 6.303

10.  What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins.

Authors:  Hillary A Vanderven; Fernanda Ana-Sosa-Batiz; Sinthujan Jegaskanda; Steven Rockman; Karen Laurie; Ian Barr; Weisan Chen; Bruce Wines; P Mark Hogarth; Teresa Lambe; Sarah C Gilbert; Matthew S Parsons; Stephen J Kent
Journal:  EBioMedicine       Date:  2016-04-28       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.